Transesophageal Echocardiography-Guided Cardioversion Safety Protocols

Atrial fibrillation (AF) cardioversion can restore sinus rhythm promptly, yet the procedure carries a clinically important risk of thromboembolism when clot has formed in the left atrium or left atrial appendage. Transesophageal echocardiography (TEE) offers a rapid imaging strategy for selected patients whose anticoagulation history is uncertain, inadequate, or shorter than the conventional pre-cardioversion period.

TEE-guided cardioversion is not a substitute for structured assessment. Safe practice combines rhythm history, anticoagulant verification, echocardiographic interpretation, airway preparation, procedural monitoring, and a clear plan for anticoagulation after the shock. The approach is relevant across Australian metropolitan and regional services, where access to cardiac anaesthesia, echocardiography, and electrophysiology may vary.

Selecting Patients For A TEE-Guided Strategy

The conventional pathway generally requires therapeutic anticoagulation for at least three weeks before cardioversion when AF has lasted longer than 48 hours or its duration is unknown. A TEE-guided strategy may shorten the time to rhythm restoration by checking for left atrial thrombus, provided the patient can undergo sedation, oesophageal imaging, and immediate cardioversion if the findings are suitable.

The decision should account for haemodynamic status, symptom burden, AF duration, previous stroke or transient ischaemic attack, heart failure, renal function, bleeding risk, and the reliability of medication use. Haemodynamic instability, ongoing myocardial ischaemia, or pulmonary oedema requires urgent management and should not be delayed by an elective imaging pathway. In Australia, the local hospital protocol, cardiology service, and availability of an appropriately credentialled echocardiographer will influence whether TEE can be arranged promptly in Sydney, Melbourne, Brisbane, or a regional centre.

Anticoagulation Verification Before Imaging

A medication list is not enough. The team should establish the last dose, prescribed regimen, missed doses, recent interruptions, renal function, and potential interactions. For warfarin, the international normalised ratio (INR) history should demonstrate adequate therapeutic control. For a direct oral anticoagulant (DOAC), clinicians should confirm adherence and dosing suitability rather than infer protection from a prescription alone.

Anticoagulation should usually continue before and after cardioversion according to thromboembolic risk and the selected guideline pathway. A negative TEE excludes visible thrombus at the time of imaging, but it does not remove the risk associated with atrial stunning after rhythm conversion. Australian clinicians may also need to consider Pharmaceutical Benefits Scheme access, hospital formulary restrictions, medication affordability, and whether a patient discharged to a rural or remote area can obtain uninterrupted therapy.

Performing And Interpreting The TEE

TEE should be performed by a trained operator using a systematic examination of the left atrium and left atrial appendage. The probe assessment should look for thrombus, dense spontaneous echo contrast, appendage emptying abnormalities, and other findings that may indicate blood stasis. Colour Doppler and pulsed-wave Doppler can help assess appendage flow, although a low flow velocity is a risk marker rather than an automatic diagnosis of clot.

A thrombus in the left atrial appendage should lead to cancellation or deferral of cardioversion, with therapeutic anticoagulation and repeat imaging planned according to the clinical situation. Suspicious material should not be dismissed as artefact, pectinate muscle, or sludge without adequate views and expert review. The report should document image quality, the presence or absence of thrombus, spontaneous echo contrast, appendage visualisation, and any limitation that prevents confident exclusion.

Preparing For Sedation And Electrical Shock

TEE and cardioversion require coordinated preparation. Confirm fasting status, allergies, airway risk, dentition, prior oesophageal disease, consent, intravenous access, baseline observations, and the intended sedation or anaesthesia plan. Oesophageal stricture, active upper gastrointestinal bleeding, recent oesophageal surgery, perforation risk, and severe swallowing disorders may make TEE inappropriate or require specialist discussion.

Continuous ECG, oxygen saturation, blood pressure, and appropriate respiratory monitoring should be used throughout sedation and recovery. Defibrillation pads should be positioned before the procedure, with resuscitation equipment and trained staff immediately available. In Australian hospitals, this may involve a cardiologist, cardiac sonographer, anaesthetist or credentialled sedation practitioner, nursing staff, and a recovery area capable of managing airway complications. The plan should also address whether the patient can travel home safely and who will supervise them after discharge.

Delivering Cardioversion Safely

Synchronised direct-current cardioversion should be delivered with the shock timed to the R wave, reducing the risk of inducing ventricular fibrillation. Pad placement, device checks, energy selection, and escalation strategy should follow local policy and the patient’s rhythm, body habitus, implanted devices, and clinical condition. A single successful shock is not guaranteed, and repeated attempts should be balanced against sedation exposure and the likelihood of early AF recurrence.

The team should verify sinus rhythm on the ECG rather than relying on pulse palpation alone. Bradycardia, pauses, atrioventricular block, hypotension, pulmonary oedema, and ventricular arrhythmia can occur after conversion, particularly in patients with conduction disease or structural heart disease. Pacemaker and implantable cardioverter-defibrillator patients need device-specific precautions, including appropriate pad distance and post-procedure interrogation when indicated.

Managing The Immediate Recovery Period

Recovery monitoring should continue until consciousness, airway reflexes, oxygenation, circulation, and mobility have returned to an acceptable baseline. Chest discomfort, dysphagia, odynophagia, persistent hypoxia, neurological symptoms, and unexpected haemodynamic changes require assessment rather than routine reassurance. A new focal neurological deficit or sudden confusion should be treated as a possible embolic event and escalated urgently.

The discharge record should state the rhythm achieved, TEE findings, cardioversion energy and number of shocks, complications, anticoagulant instructions, and follow-up arrangements. Patients need clear advice not to drive, operate machinery, drink alcohol, or make important decisions for the period specified by the sedation protocol. Plain terminology matters when explaining the difference between cardioversion, defibrillation, ablation, and device therapy; even general terminology resources show how unfamiliar vocabulary can create avoidable confusion.

Continuing Anticoagulation And Follow-Up

At least four weeks of anticoagulation after cardioversion is commonly required because atrial mechanical function can remain impaired after the ECG has normalised. Longer-term treatment depends on the patient’s stroke-risk profile and not simply on whether sinus rhythm was restored. Recurrence of AF is common, so follow-up should review symptoms, pulse or rhythm monitoring, medication adherence, bleeding, blood pressure, sleep apnoea, alcohol intake, weight, and other modifiable contributors.

A discharge pathway should specify who reviews anticoagulation, when renal function or INR is checked, and what happens if AF returns. Remote patients may need telehealth support, coordination with a general practitioner, and practical arrangements for pathology or medication supply. The wider rhythm-care environment includes pacing, ablation, wearable monitoring, and defibrillator therapy; clinicians can explore related developments through the journal’s special issues, while recognising that a wearable cardioverter-defibrillator is a distinct technology with different indications, including selected paediatric situations discussed in paediatric device care.

TEE-guided cardioversion is safest when treated as a complete clinical pathway rather than a single imaging test. A visible thrombus, uncertain anticoagulant exposure, inadequate imaging, unstable physiology, or insufficient recovery support should prompt deferral and senior review. Conversely, a carefully documented negative examination, appropriate anticoagulation, controlled sedation, synchronised shock delivery, and structured follow-up can make urgent rhythm restoration a well-governed option for selected patients with AF.

Clinicians, trainees, and researchers can use peer-reviewed arrhythmia literature to refine local protocols, compare anticoagulation strategies, and align cardioversion practice with contemporary electrophysiology standards across Australia and the wider Asia-Pacific region.